A Gene Therapy paper described adenine base editing (ABE) that corrects a cryptic splice mutation linked to cardiac-type Fabry disease in cells. Researchers targeted the IVS4+919 G>A mutation site, using ABE to restore the intended RNA processing pathway and address the underlying genetic defect rather than treating symptoms. The key outcome is mutation-level correction with a functional restoration goal, supported by the study’s experimental design focused on splice correction. For gene-editing developers, it adds another data point showing how ABE can be extended beyond straightforward base substitutions into clinically relevant splice contexts. While cell-based, the result strengthens the rationale for moving splice-correction strategies into preclinical and in vivo work where delivery and off-target profiles remain central hurdles.